Treatment of TASC C and D Aortoiliac Lesions
Launched by CLINICAL CENTRE OF SERBIA · Feb 2, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying different treatment options for patients with complex aortoiliac disease, a condition that affects blood flow in the legs and can lead to serious problems. The researchers want to compare three treatment methods: open surgery, a combination of surgery and stenting (hybrid repair), and a fully endovascular approach (using minimally invasive techniques). They hope to find out which method works best for improving patient outcomes while keeping risks low, especially for those who may not be able to tolerate major surgery due to health concerns.
To be eligible for this trial, participants must be over 18 years old and have a history of narrowing or blockage in their leg arteries due to atherosclerosis (a build-up of fat in the arteries). The study is open to all patients treated between January 2015 and January 2022, and it includes both those who have had surgery and those who have had other types of treatment. Participants can expect to provide information about their health and treatment experiences, and the study will track their progress over time to see how well each treatment works. This research is important as it aims to improve care for people with serious leg circulation issues.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All patients (over 18 years of age) with a history of atherosclerotic peripheral arterial disease treated between 1st January 2015 and 1st January 2022
- • All management strategies will be included (endovascular, hybrid, and open)
- Exclusion Criteria:
- • Patients who are pregnant
- • Patients who are under 18 years of age
- • Patients who have acute limb ischemia or acute on chronic ischemia
- • Non-atherosclerotic origin of disease: cyclist disease, trauma, dissection
- • Patients who were treated in conservative manner
- • Patients who underwent primary major amputation
- • Patients with limited life expectancy (less than 2 years)
About Clinical Centre Of Serbia
The Clinical Centre of Serbia is a leading healthcare institution dedicated to advancing medical research and improving patient care through innovative clinical trials. As a prominent sponsor of clinical studies, the Centre emphasizes rigorous scientific methodology and ethical standards, fostering collaborations with local and international research organizations. With a multidisciplinary team of experienced researchers and clinicians, the Clinical Centre of Serbia aims to contribute to the development of new therapeutic interventions and enhance clinical practices, ultimately benefiting patient populations in Serbia and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Belgrade, , Serbia
Patients applied
Trial Officials
Joao Rocha Neves, MD PhD
Study Director
Univeristy of Porto
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported